E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 9/13/2005 in the Prospect News Biotech Daily.

Pfizer maintained by Bear Stearns at outperform

Pfizer Inc. was maintained by Bear Stearns analyst John Boris at an outperform rating with a price target on the stock of $34 per share following the FDA panel vote to approve Exubera, an inhaled insulin, for treatment of Type 1 and Type 2 diabetes. Pfizer shares Tuesday were down $0.36, or 1.37%, at $25.98 on volume of 17,656,100 shares versus the three-month running average of 24,344,100 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.